Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris

Main Article Content

James Q Del Rosso
Corey L Hartman
Caitlin Lewis
Rhonda Schreiber

Keywords

acne, tazarotene

Abstract

Abstract not available.

References

1. Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, Leutenegger E, Perez M. Global Alliance to Improve Outcomes in Acne Large scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010 Apr;49(4):448-56.

2. Kircik LH. Importance of vehicles in acne therapy. J Drugs Dermatol. 2011 Jun;10(6):s17-23.

3. Del Rosso JQ, Kircik LH, Zeichner J, Stein Gold L. The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles Vehicle Characteristics Can Influence and Improve Patient Outcomes. J Drugs Dermatol. 2019 Feb 1;18(2s):s100-s107.

4. Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014 Jul;94(1):46-53.

5. Smith JA, Narahari S 2 Hill D, Feldman SR. Tazarotene foam, 0.1% for the treatment of acne. Expert Opin Drug Saf. 2016 Jan;15(1):99-103.

6. Feldman SR, Werner CP, Alió Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1% in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013 Apr:12(4):438-46.

7. Epstein EL, Stein Gold L. Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. Clin Cosmet Investig Dermatol. 2013 May;14(6):123-5.

8. Data on file, Mayne Pharma